Altimmune, Inc. Overview
Pro stress-test →Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis.
Strategic Profile
Pro stress-test →Altimmune has received FDA Breakthrough Therapy Designation for its treatment pemvidutide, showing promising results in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). The company is set to enter a Phase 3 trial, aiming for accelerated approval, while analysts predict a substantial upside for the stock.
Competitive Landscape
Pro stress-test →Altimmune competes in the high-growth GLP-1 agonist market against companies developing similar metabolic therapeutics. Key competitors include Viking Therapeutics, Zenas BioPharma, and larger pharma players entering obesity/MASH space. Altimmune's differentiation lies in its balanced dual glucagon/GLP-1 mechanism and Breakthrough Therapy designation, positioning it as a potential alternative to existing therapies.
Industry Context
Altimmune, Inc. operates in Biopharmaceutical - Clinical Stage Drug Development.
Key facts
Founded: 1997 · Headquarters: Gaithersburg, Maryland, US · Revenue: $20,000 (2024)